Maurea S, Cuocolo A, Reynolds J, Keiser H, Neumann R, Salvatore M
Istituto Nazionale dei Tumori di Napoli.
Radiol Med. 1994 May;87(5):688-93.
In order to evaluate 131I metaiodobenzylguanidine (MIBG) uptake in patients with benign or malignant paragangliomas, 28 patients (14 men and 14 women, mean age 37 +/- 10 years) with benign (no. = 15; group 1) or malignant (no. = 13; group 2) tumors underwent MIBG scintigraphy. A total of 110 lesions (20 benign and 90 malignant) were studied. In all patients histologic disease confirmation was obtained. MIBG uptake was quantified on 48 hours' images (Kodak NMC-1 films) using a photographic densitometer. The optical densities of tumor and adjacent or contralateral normal tissue were used to calculate the MIBG uptake intensity ratio for each lesion. In group 1, all patients exhibited 1 or 2 lesions with abnormal MIBG uptake. In group 2, all patients had 1 to 28 abnormal foci of MIBG uptake. In the patients with 2 or more lesions, the average MIBG uptake intensity ratio was calculated. MIBG uptake intensity ratio was significantly higher in malignant than in benign paragangliomas (5.2 +/- 2.4 vs 2.9 +/- 1.4, p < 0.01). Since MIBG uptake in paragangliomas reflects the intratumoral concentration of catecholamines, higher MIBG uptake in malignant lesions suggests a greater amount of stored catecholamines in these tumors. In conclusion, 131I MIBG scintigraphy may be useful to distinguish benign from malignant paragangliomas.
为了评估131I间碘苄胍（MIBG）在良性或恶性副神经节瘤患者中的摄取情况，28例患者（14例男性和14例女性，平均年龄37±10岁）患有良性（n = 15；第1组）或恶性（n = 13；第2组）肿瘤，接受了MIBG闪烁显像。共研究了110个病灶（20个良性和90个恶性）。所有患者均获得了组织学疾病确诊。使用照相密度计在48小时图像（柯达NMC - 1胶片）上对MIBG摄取进行定量。肿瘤以及相邻或对侧正常组织的光密度用于计算每个病灶的MIBG摄取强度比。在第1组中，所有患者均表现出1个或2个病灶有异常MIBG摄取。在第2组中，所有患者有1至28个MIBG摄取异常灶。对于有2个或更多病灶的患者，计算平均MIBG摄取强度比。恶性副神经节瘤的MIBG摄取强度比显著高于良性副神经节瘤（5.2±2.4对2.9±1.4，p < 0.01）。由于副神经节瘤中的MIBG摄取反映了肿瘤内儿茶酚胺的浓度，恶性病灶中较高的MIBG摄取表明这些肿瘤中储存的儿茶酚胺量更大。总之，131I MIBG闪烁显像可能有助于区分良性和恶性副神经节瘤。
